Login Register
icon_bulk_orderBulk order Acrobiosystems for English
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > gp130


Brief Information

Name:Interleukin-6 receptor subunit beta
Target Synonym:IL6ST,Oncostatin-M Receptor Subunit Alpha,CD130,Interleukin-6 Signal Transducer,Interleukin-6 Receptor Subunit Beta,Gp130 Of The Rheumatoid Arthritis Antigenic Peptide-Bearing Soluble Form,CD130 Antigen,Membrane Glycoprotein Gp130,SGP130,IL-6R-Beta,HIES4,Gp130, Oncostatin M Receptor,IL-6RB,GP130,Cytokine Receptor gp130,Interleukin 6 Signal Transducer,Membrane Glycoprotein 130,Interleukin 6 Signal Transducer (Gp130, Oncostatin M Receptor),CDW130,IL-6 Receptor Subunit Beta,Interleukin Receptor Bet
Number of Launched Drugs:3
Number of Drugs in Clinical Trials:12
Lastest Research Phase:Approved

Product ListCompare or Buy

Part of Bioactivity data

gp130 MALS images

The purity of Human gp130, His Tag (Cat. No. ILT-H52H2) is more than 90% and the molecular weight of this protein is around 85-105kDa verified by SEC-MALS.

 gp130 ELISA

Immobilized Biotinylated Human IL-6 R alpha, Fc,Avitag (Cat. No. ILR-H82F9) can bind Human gp130, His Tag (Cat. No. ILT-H52H2) with a linear range of 0.005-0.313 μg/mL (QC tested).

Synonym Name



Interleukin-6 receptor subunit beta (IL6ST) is also known as IL-6 receptor subunit beta, IL-6R subunit beta, IL-6R-beta, IL-6RB, Interleukin-6 signal transducer, Membrane glycoprotein 130 (gp130), CD130, Oncostatin-M receptor subunit alpha and Il6st,which is single-pass type I membrane protein. IL6ST /gp130 /CD130 can be found in tissues such as brain, heart, thymus, spleen, kidney, lung and liver and found in all the cell lines tested except BaF-B03.The expression of IL-6ST /gp130 is not restricted to IL6-responsive cells. The receptor systems for IL6, LIF, OSM, CNTF, IL11, CTF1 and BSF3 can utilize gp130 for initiating signal transmission. IL6ST /CD130 can bind to IL6 /IL6R (alpha chain) complex, resulting in the formation of high-affinity IL6 binding sites, and transduce the signal. IL6ST /GP130 does not bind IL6 and may have a role in embryonic development.

Clinical and Translational Updates

Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Sarilumab REGN-88; SAR-153191 Approved Sanofi, Regeneron Pharmaceuticals Inc Kevzara Japan Arthritis, Rheumatoid Sanofi 2017-05-22 Arthritis, Rheumatoid Details
Satralizumab RG-6168; SA-237 Approved Chugai Pharmaceutical Co Ltd Enspryng, エンスプリング EU Neuromyelitis Optica Roche Registration Gmbh 2020-06-29 Myasthenia Gravis; Neuromyelitis Optica Details
Tocilizumab MRA; HPM-1; MRA-SC; R-1569; rhPM-1; RG-1569; RO-48775533 Approved Chugai Pharmaceutical Co Ltd Actemra/RoActemra, 雅美罗, Actemra, RoActemra EU Coronavirus Disease 2019 (COVID-19) Roche Registration Gmbh 2005-04-11 Lymphoma, Non-Hodgkin; Polymyalgia Rheumatica; Urinary Bladder Neoplasms; Rejection of organ transplantation; Coronavirus Infections; Neuromyelitis Optica; Severe Acute Respiratory Syndrome; Coronary Disease; Takayasu Arteritis; Pulmonary Arterial Hypertension; Breast Neoplasms; Lymphoma, Follicular; Multicentric Castleman's Disease (MCD); systemic sclerosis-associated interstitial lung disease; Fever; Colorectal Neoplasms; Arthritis, Juvenile; Rejection in heart transplantation; Pulmonary Disease, Chronic Obstructive; Osteoarthritis; Uveitis; Uveitis, Posterior; Leukemia, Myeloid, Acute; Inflammation; Carcinoma, Squamous Cell; Lymphoma; Non-ST Elevated Myocardial Infarction; Kidney Failure, Chronic; Carcinoma, Hepatocellular; Diabetes Mellitus; Behcet Syndrome; Amyotrophic Lateral Sclerosis; Dermatomyositis; Rejection of renal transplantation; HIV Infections; Liver Neoplasms; Polymyositis; Craniopharyngioma; Hematopoietic stem cell transplantation (HSCT); Cytokine Release Syndrome; Motor Neuron Disease; Fam Details

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
Tocilizumab Biosimilar (qyuns) QX-003-S Phase 1 Clinical Arthritis, Rheumatoid Details
Tocilizumab biosimilar (AryoGen Pharmed) Phase 3 Clinical Aryogen Biopharma Arthritis, Rheumatoid Details
CMAB806 CMAB-806 Phase 3 Clinical Taizhou Maibo Taike Biotechnology Co Ltd Arthritis, Rheumatoid; Arthritis Details
Recombinant humanized anti-IL-6R antibody (Hisun Pharma) HS-628 Phase 3 Clinical Zhejiang Hisun Pharmaceutical Co Ltd Arthritis, Rheumatoid; Arthritis Details
Atexakin alfa SON-080; r-IL-6 Phase 2 Clinical Merck Serono, Weizmann Institute Of Science Peripheral Nervous System Diseases; Diabetic Neuropathies Details
Vobarilizumab ALX-0061; ANTI-IL-6R; 20A11-9mer-ALB11; Anti-IL-6R Nanobody Ablynx Details
VDJ-001 Phase 2 Clinical Beijing Vdjbio Co Ltd Arthritis, Rheumatoid; Multicentric Castleman's Disease (MCD) Details
Tocilizumab biosimilar (Fresenius kabi) MSB-11456 Phase 3 Clinical Merck Serono Arthritis, Rheumatoid Details
Olamkicept FE-301; TJ-301; CR-5/18; FE-999301 Phase 2 Clinical Conaris Research Institute Colitis, Ulcerative Details
Levilimab BCD-089 Phase 3 Clinical Biocad Coronavirus Disease 2019 (COVID-19); Arthritis, Rheumatoid Details

This web search service is supported by Google Inc.

Call us
Call us
North America: +1 800-810-0816 (Toll Free)
Asia & Pacific: +86 400-682-2521
+1 888-377-6111
1 Innovation Way, Newark, DE 19711, USA

Leave a message